MTOR and pancreatic neoplasm: Preclinical studies in pancreatic cancer cell lines displayed diverse effects of mTOR inhibitors on cell cycle progression, autophagy, reduced inflammation and inhibition of epithelial-to-mesenchymal transition [62–65].